文献速递心力衰竭与心肌病

维利西呱用于接受慢性间歇性左西孟旦输注的晚期心衰患者:前瞻性试点研究

Vericiguat in advanced heart failure patients receiving chronic intermittent levosimendan infusions: a prospective pilot study.
PubMed 文献 · Heart · 2025-12-11

本研究前瞻性评估维利西呱在每月接受左西孟旦输注的晚期心衰患者中的安全性与耐受性,18例中8例符合用药条件,用药者超声心动图、生活质量和1年死亡率优于非用药者,但37.5%因症状性低血压停药。

要点

  • 晚期心衰合并慢性左西孟旦输注患者中,维利西呱总体耐受,无严重不良事件。
  • 37.5%用药患者因症状性低血压停药,需密切监测血压。
  • 符合条件者超声心动图、生活质量和1年死亡率优于非符合条件者。

核心结论

  • 首次提供前瞻性证据支持维利西呱在慢性左西孟旦治疗的晚期心衰患者中安全使用,但需警惕低血压。

研究设计与样本

  • 前瞻性试点研究,纳入18例每月接受左西孟旦输注的晚期心衰患者,其中8例符合维利西呱用药条件。

主要发现

  • 8例符合条件并接受维利西呱的患者超声心动图表现更好、生活质量改善且1年死亡率更低。
  • 37.5%的患者因症状性低血压停用维利西呱。
  • 维利西呱总体耐受良好,未观察到严重不良事件。

临床怎么用

  • 对接受慢性左西孟旦输注的晚期心衰患者可考虑维利西呱,但需密切监测低血压并谨慎滴定。

局限性

  • 样本量小(18例),为试点研究,需进一步研究优化高危患者治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although treatment options for heart failure (HF) have improved, advanced HF (AdHF) remains a challenging condition, impacting over 10% of patients with a poor prognosis. In severe cases, patients may experience resistance to or intolerance of conventional therapies, leading to frequent hospitalisations and a heightened risk of death. Vericiguat, a novel treatment for HF with reduced ejection fraction (HFrEF), has shown promise in improving outcomes for patients with worsening HF. The VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial demonstrated that vericiguat can reduce the risk of adverse events in patients with EF<45% following a worsening HF event. However, its safety and efficacy in AdHF patients previously receiving chronic levosimendan infusions remain unclear. METHODS AND RESULTS: In this prospective study, we evaluated the safety and tolerability of vericiguat in AdHF patients treated with monthly levosimendan infusions at our clinic. Among 18 patients, 8 were eligible for vericiguat, which was associated with better echocardiographic findings, improved quality of life and lower 1-year mortality compared with non-eligible patients. However, 37.5% of patients discontinued the drug due to symptomatic hypotension, highlighting a key challenge in managing this fragile population. Despite this, vericiguat was generally well-tolerated, and no severe adverse effects were observed. DISCUSSION: This study provides the first prospective evidence supporting the safe use of vericiguat in AdHF patients on chronic levosimendan. However, careful monitoring for hypotension is essential, and titration may be more difficult in this population. Further research is needed to optimise treatment strategies for these high-risk patients.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Sciatti, Di Odoardo, Zucchetti, et al. Vericiguat in advanced heart failure patients receiving chronic intermittent levosimendan infusions: a prospective pilot study. Heart. 2025. PMID: 40659505. doi:10.1136/heartjnl-2025-326009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。